-
Cisapride (R 51619) in Cardiotoxicity Workflows
2026-09-04
Cisapride combines 5-HT4 receptor agonism with hERG potassium channel inhibition, making it a useful reference probe for linking pathway activation to electrical and structural cardiac phenotypes. This practical guide shows how to deploy it in iPSC-cardiomyocyte imaging, electrophysiology, and early cardiac arrhythmia research while controlling solvent, exposure, and interpretation risks.
-
Pazopanib Hydrochloride Assay Workflows
2026-09-03
Build more informative Pazopanib Hydrochloride experiments by separating growth inhibition from true cell killing and pairing dose–response curves with time-resolved endpoints. This workflow supports anti-angiogenic agent studies, renal cell carcinoma research, and soft tissue sarcoma models while highlighting practical troubleshooting steps.
-
AL-8810: Prostaglandin F2α Antagonist
2026-09-03
AL-8810 is a prostaglandin F2α antagonist that selectively targets the FP receptor for cellular and tissue research. Product benchmarks and a peer-reviewed mouse menstrual-like model support its use for dissecting FP receptor signaling, vascular responses, smooth muscle biology, and MMP-2 secretion inhibition.
-
IWR-1-endo: Practical Wnt Signaling Inhibitor Guide
2026-09-02
IWR-1-endo provides a pathway-focused way to test β-catenin-dependent proliferation, stem-cell behavior, and regeneration rather than relying on nonspecific growth suppression. This guide connects practical dosing, orthogonal readouts, and single-nucleus assay design to colorectal cancer research and exploratory tissue models.
-
Ibrexafungerp Against Resistant Candida auris
2026-09-02
Wiederhold et al. show that ibrexafungerp retained in vitro activity against 54 Candida auris isolates and improved outcomes in a neutropenic mouse model even when therapy began after infection was established. The study is important because it evaluates an orally administered glucan-synthesis inhibitor against fluconazole-resistant C. auris and benchmarks its activity against caspofungin.
-
Intravesical p21 mRNA–LNP Therapy in Bladder Cancer
2026-09-01
The reference study developed chemically modified p21 mRNA–loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. Its results connect local p21 restoration with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced tumor growth in an orthotopic mouse model, while also defining important translational limitations for mRNA delivery.
-
Annexin V: Recombinant Phosphatidylserine Probe
2026-09-01
Annexin V is a human recombinant phosphatidylserine binding protein for calcium-dependent detection of exposed phosphatidylserine in apoptosis assays. K2064 is supplied as an unlabeled 1 mg/mL liquid reagent in PBS and supports conjugation, competition binding, and cell death research workflows.
-
HATU for Precise Peptide Synthesis Chemistry
2026-08-31
HATU enables a practical, high-efficiency route to challenging amide bonds and selected ester linkages, from millimole-scale scouting to medicinal-chemistry analog production. This guide connects reagent handling and troubleshooting with the bestatin-derived inhibitor strategy reported for IRAP and ERAP1.
-
DHEA Workflows for Neuroprotection and Ovarian Assays
2026-08-31
Build reproducible DHEA experiments across ovarian and neuronal systems using concentration–time windows, vehicle controls, and mechanism-aware readouts. This guide also shows how the 2026 ferulic acid study can sharpen ER-stress and apoptosis assay design without confusing evidence for DHEA with evidence for ferulic acid.
-
Phosbind Biotin LC: Practical Western Blot Guide
2026-08-30
Phosbind Biotin LC is a phosphate-binding reagent for sequence-independent detection of phosphorylated proteins on PVDF membranes, helping address cases where phospho-specific antibodies are unavailable or overly site-specific. It should be used in a streptavidin-HRP chemiluminescent workflow and is not appropriate for water-only protocols or long-term storage of working solutions.
-
Prednisone Research Workflows & Troubleshooting
2026-08-29
Prednisone gives immunology researchers a practical way to model G1 arrest, IL-2 pathway suppression, and lymphocyte apoptosis in controlled in vitro systems. This guide combines mechanistic PBL workflows with LC–MS/MS-inspired matrix controls to improve dosing accuracy, reproducibility, and translational interpretation.
-
RNA G-Quadruplexes Shape TDP-43 Toxicity
2026-08-28
The 2025 Structure study by Oldani and colleagues shows that RNA G-quadruplexes directly influence TDP-43 aggregation, intracellular distribution, and toxicity across biochemical and cellular models. Its findings position RNA structure modulation as a mechanistic avenue for neurodegeneration research while highlighting the need to distinguish RNA G-quadruplex biology from DNA-focused stabilization strategies.
-
Ibrexafungerp Against Fluconazole-Resistant Candida auris
2026-08-28
Wiederhold and colleagues evaluated ibrexafungerp against fluconazole-resistant Candida auris using both susceptibility testing and a delayed-treatment murine model of invasive candidiasis. The study connects consistent in vitro activity with improved survival and reduced kidney fungal burden, supporting further investigation of orally active glucan-synthesis inhibitors for resistant Candida infections.
-
Separating Growth Arrest from Cancer Cell Killing
2026-08-27
Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability capture different components of an in vitro cancer-drug response: proliferative arrest and cell killing. By emphasizing response magnitude, composition, and timing, the study offers a more rigorous framework for interpreting drug-response assays and designing follow-up experiments.
-
Ibrexafungerp Against Fluconazole-Resistant C. auris
2026-08-27
Wiederhold and colleagues combined susceptibility testing with a delayed-treatment murine model to examine ibrexafungerp against fluconazole-resistant Candida auris. The study found consistent in vitro activity and meaningful in vivo effects despite postponement of therapy, supporting further evaluation of orally administered glucan-targeting antifungal strategies.